Wave Life Sciences price to sales ratio WVE
Market value divided by revenue over the last twelve months, since 2017.
- Today, Nov 2, 2026
- 9.8×
- 9-year median
- 20.3×
- Against its 9-year history
- 24th
- percentile: 0 is its lowest day, 100 its highest
- 9-year range
- 1.8× to 197×
- Peer median
- 1.6×
Wave Life Sciences' price to sales ratio is 9.8× as of Nov 2, 2026.
That is below its 9-year median of 20.3×, lower than on 76% of days in the last 9 years.
Over that time it ranged from 1.8× in May 2022 to 197× in Aug 2017.
The median for 10 large drugmakers of a similar size is 1.6×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 9.8× | 9.8× | 10.0× |
| 2025 | 14.6× | 14.6× | 18.6× |
| 2024 | 17.8× | 4.5× | 21.1× |
| 2023 | 5.9× | 5.1× | 121× |
| 2022 | 146× | 1.8× | 146× |
| 2021 | 13.7× | 13.7× | 43.2× |
| 2020 | 29.4× | 14.2× | 56.9× |
| 2019 | 31.5× | 30.4× | 109× |
| 2018 | 99.9× | 87.7× | 181× |
| 2017 | 197× | 197× | 197× |
Against its peers
Companies in Drug Manufacturers - General nearest Wave Life Sciences' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| WVEWave Life Sciences | 9.8× |
| COLLCollegium Pharmaceutical | 1.0× |
| ABUSArbutus Biopharma | 4.4× |
| ZVRAZevra Therapeutics | 4.4× |
| IRWDIronwood Pharmaceuticals | 1.5× |
| PBYIPuma Biotechnology | 2.3× |
| ARVNArvinas | 1.6× |
| CRMDCorMedix | 0.9× |
| AMPHAmphastar Pharmaceuticals | 1.6× |
| OMEROmeros | n/m |
| ANABAnaptysbio | n/m |
| Peer median | 1.6× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Wave Life Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.